Radical prostatectomy, external beam radiotherapy &lt;72 Gy, external beam radiotherapy ≥72 Gy, permanent seed implantation, or combined seeds/external beam radiotherapy for stage T1–T2 prostate cancer

Kupelian, Patrick A.; Potters, Louis; Khuntia, Deepak; Ciezki, Jay P.; Reddy, Chandana A.; Reuther, Alwyn M.; Carlson, Thomas P.; Klein, Eric A.

doi:10.1016/s0360-3016(03)00784-3

Cited by 429 publications

(159 citation statements)

References 28 publications

Supporting

Mentioning

143

Contrasting

Unclassified

Order By: Relevance

“…Los resultados en sobrevida global, 85% a 5 años, y sobrevida libre de enfermedad, 83% a cinco años, obtenidos en nuestra serie son similares a los reportados por series extranjeras 3,5,16 . La serie de escalamiento de dosis del MD Anderson comunica para los pacientes tratados con 78 Gy una sobrevida libre de falla bioquímica a 5 años de 85% y 78% a 8 años 16 .…”

Section: Discussionunclassified

See 1 more Smart Citation

Tratamiento del cáncer de próstata con radioterapia por modulación de intensidad, primera experiencia en Chile

Besa

et al. 2011

Rev. méd. Chile

View full text Add to dashboard Cite

show abstract

Section: Discussionunclassified

“…No está bien defi nida la indicación de cada modalidad de tratamiento. Grandes series no aleatorias demuestran que los resultados del tratamiento con prostatectomía o radioterapia son similares [2][3][4] . No contamos con resultados de tratamiento para la radioterapia moderna en Chile.…”

unclassified

Tratamiento del cáncer de próstata con radioterapia por modulación de intensidad, primera experiencia en Chile

Besa

et al. 2011

Rev. méd. Chile

View full text Add to dashboard Cite

show abstract

“…14 The median follow-up was 56 months. The 5-year bNED rates were 51% for an EBRT dose <72 Gy, 81% for an EBRT dose !72 Gy, 83% for BRT, and 77% for EBRT þ BRT.…”

Section: Discussionmentioning

confidence: 99%

“…In addition, the bNED rates of our BRT cases were comparable to large published series from experienced centers, suggesting that the quality of our implants should be acceptable. 13,14 Conclusions Dose escalation from conventional dose 3D-CRT can be achieved with IMRT, BRT, or EBRT þ BRT. Data from the current study indicate that there is a dose-response effect in the bNED rate for patients with intermediaterisk prostate cancer.…”

Section: Discussionmentioning

confidence: 99%

Radiation dose escalation for localized prostate cancer

Wong

Vora

Schild

et al. 2009

Cancer

View full text Add to dashboard Cite

BACKGROUND:In the current study, the effects of dose escalation for localized prostate cancer treatment with intensity‐modulated radiotherapy (IMRT) or permanent transperineal brachytherapy (BRT) in comparison with conventional dose 3‐dimensional conformal radiotherapy (3D‐CRT) were evaluated.METHODS:This study included 853 patients; 270 received conventional dose 3D‐CRT, 314 received high‐dose IMRT, 225 received BRT, and 44 received external beam radiotherapy (EBRT) + BRT boost. The median radiation doses were 68.4 grays (Gy) for 3D‐CRT and 75.6 Gy for IMRT. BRT patients received a prescribed dose of 144 Gy with iodine‐125 (I‐125) or 120 Gy with palladium‐103 (Pd‐103), respectively. Patients treated with EBRT + BRT received 45 Gy of EBRT plus a boost of 110 Gy with I‐125 or 90 Gy with Pd‐103. Risk group categories were low risk (T1‐T2 disease, prostate‐specific antigen level ≤10 ng/mL, and a Gleason score ≤6), intermediate risk (increase in value of 1 of the factors), and high risk (increase in value of ≥2 factors).RESULTS:With a median follow‐up of 58 months, the 5‐year biochemical control (bNED) rates were 74% for 3D‐CRT, 87% for IMRT, 94% for BRT, and 94% for EBRT + BRT (P <.0001). For the intermediate‐risk group, high‐dose IMRT, BRT, or EBRT + BRT achieved significantly better bNED rates than 3D‐CRT (P <.0001), whereas no improvement was noted for the low‐risk group (P = .22). There was no increase in gastrointestinal (GI) toxicity from high‐dose IMRT compared with conventional dose 3D‐CRT, although there was more grade 2 genitourinary (GU) toxicity (toxicities were graded at the time of each follow‐up visit using a modified Radiation Therapy Oncology Group [RTOG] scale). BRT caused more GU but less GI toxicity, whereas EBRT + BRT caused more late GU and GI toxicity than IMRT or 3D‐CRT.CONCLUSIONS:The data from the current study indicate that radiation dose escalation improved the bNED rate for the intermediate‐risk group. IMRT caused less acute and late GU toxicity than BRT or EBRT + BRT. Cancer 2009. © 2009 American Cancer Society.

show abstract

“…In low-risk prostate cancer patients, the rate of biological recurrence-free survival after radiation therapy have been comparable to that of radical prostatectomy. 1 It was reported that conventional radiotherapy tended to fail in treating patients with concentrations of prostate-specific antigen over 15. 2 As local recurrence after radiotherapy remains a reality, improvement of treatment strategies is necessary to manage the local and micro-metastatic lesions of prostate cancer.…”

Section: Introductionmentioning

confidence: 99%

Regulation of gene expression in prostate cancer cells with an artificially constructed promoter responsive to radiation

et al. 2011

View full text Add to dashboard Cite

A promoter library was developed that is composed of DNA fragments constructed by randomly elongating the cis-acting elements of transcription factors presumably activated in prostate cancer by radiation, and linking to the TATA-box sequence. One promoter with the strongest reactivity to X-ray in the LNCap cells of the library was chosen and improved by the introduction of random mutations. The resultant promoter was designated clone 880-8, showing the highest dose-dependent activity enhancement with X-ray irradiation (X-irradiation). A recombinant retrovirus expressing the luciferase gene under the control of clone 880-8 was infected into LNCap cells that showed 9.12±0.36-fold enhancement of luciferase activity 12 h after X-irradiation at 10 Gy. When the infected cells were inoculated onto nude mice, enhancement of luciferase expression was 4.27 ± 1.36-fold 12 h after X-irradiation at 10 Gy. When LNCap was infected with another recombinant carrying the fcy::fur gene downstream from clone 880-8, fcy::fur expression was enhanced by X-irradiation. It was also shown to increase the dosedependent cell killing ratio with 5-FC as compared with a counterpart without X-irradiation. These results suggest that the method used in this study is effective to construct a promoter responsive to stimulation. Such promoters can be used for stimulation-controlled gene therapies.

show abstract

Radical prostatectomy, external beam radiotherapy <72 Gy, external beam radiotherapy ≥72 Gy, permanent seed implantation, or combined seeds/external beam radiotherapy for stage T1–T2 prostate cancer

Cited by 429 publications

References 28 publications

Tratamiento del cáncer de próstata con radioterapia por modulación de intensidad, primera experiencia en Chile

Tratamiento del cáncer de próstata con radioterapia por modulación de intensidad, primera experiencia en Chile

Radiation dose escalation for localized prostate cancer

Regulation of gene expression in prostate cancer cells with an artificially constructed promoter responsive to radiation

Contact Info

Product

Resources

About